
Navidea Biopharmaceuticals Investor Relations Material
Latest events

EGM 2024
Navidea Biopharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Navidea Biopharmaceuticals Inc
Access all reports
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing precision immunodiagnostic agents and immunotherapeutics. Its primary technology platform, Manocept, is designed to target the CD206 receptor found on activated macrophages, which plays a key role in diagnosing and treating diseases such as cancer, autoimmune conditions, and inflammatory diseases. The company operates through two main segments: Diagnostic Substances, which include imaging agents, and Therapeutic Development Programs, aimed at therapeutic applications of its platform. Navidea is headquartered in Dublin, Ohio, and its shares are traded on the OTC Markets.
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
NAVB
Country
🇺🇸 United States